 DALLAS, July 27, 2021 PRNewswire -- Lantern Pharma NASDAQ: LTRN, a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence A.I. platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced it has entered into an Asset Purchase Agreement to reacquire global development and commercialization rights for Irofulven LP-100 from Allarity, formerly known as Oncology Venture. 